Leinco Technologies

Anti-Human CD64 (FCGR1) - DyLight® 488

Product Code:
 
LEI-C700
Product Group:
 
Primary Antibodies
Host Type:
 
Mouse
Antibody Isotype:
 
IgG1 κ
Antibody Clonality:
 
Monoclonal
Antibody Clone:
 
10.1
Regulatory Status:
 
RUO
Target Species:
 
Human
Application:
 
Flow Cytometry
Storage:
 
This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
 

No additional charges, what you see is what you pay! *

CodeSizePrice
LEI-C700-100ug100 ug£247.00
Quantity:
Prices exclude any Taxes / VAT
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: US.
Typical lead time: 14-21 working days.
Contact us for more accurate information.
  • Further Information
  • References
  • Show All

Further Information

Antigen Distribution:
FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes.
Concentration:
0.2 mg/ml
Conjugate/Tag/Label:
DyLight® 488
Format:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Formulation:
This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Immunogen:
Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
Long Description:
FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1,3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5.
NCBI Gene:
2209
Target:
CD64

References

1. Hulett MD & Hogarth PM. (1998) Mol Immunol. 35(14-15):989-96 2. M. Da?ron., et al. (2009) Blood. 113: 3716?3725 3. Alter G., et al. (2011) Epub. 415(2):160-7 4. Barth S., et al. (2017) Biomedicines. 5(3):56 5. Keler T., et al. (1998) Clin Cancer Res. 4(9):2237-43